Helius Medical Technologies, Inc. to Present at the Noble Capital Markets 17th Annual Small & Microcap Investor Conference
January 15 2021 - 12:37PM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced that management will participate in the
Noble Capital Markets 17th Annual Small & Microcap Investor
Conference, which is being held virtually from January 19th-20th.
Management will present on Tuesday, January 19th at 11:15 a.m.
Eastern Time.
A live audio webcast of the conference
presentation will be available on the Noble conference website
following free registration:
https://www.nobleconference.com/register/investor-guest. An archive
of the webcast will be available following the conference under the
‘Events’ section of the Helius Medical Technologies investor
relations website at
https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech
company focused on neurological wellness. The Company’s purpose is
to develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNS™). For more information, visit
www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™)
is authorized for sale in Canada as a class II, non-implantable,
medical device intended as a short term treatment (14 weeks) of
gait deficit due to mild and moderate symptoms from multiple
sclerosis (MS), and chronic balance deficit due to mild-to-moderate
traumatic brain injury (mmTBI) and is to be used in conjunction
with physical therapy. The PoNS™ is an investigational medical
device in the United States, the European Union (“EU”), and
Australia (“AUS”). The device is currently under review for
clearance by the FDA. It is also under premarket review by the AUS
Therapeutic Goods Administration. PoNS™ is currently not
commercially available in the United States, the European Union or
Australia.
Investor Relations Contact:
Westwicke on behalf of Helius Medical Technologies, Inc.Jack
Powellinvestorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2023 to Mar 2024